(Q33887361)

29 July 2017

1 reference

title

Toxicity in head and neck cancer: a review of trends and issues (English)

1 reference

29 July 2017

0 references

1 reference

1 reference

head and neck carcinoma

1 reference

Trotti A

1

1 reference

PubMed ID

10758302

29 July 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

International Journal of Radiation Oncology Biology Physics

29 July 2017

1 reference

29 July 2017

47

1 reference

29 July 2017

1

1 reference

29 July 2017

1-12

1 reference

Toxicity antagonists in cancer therapy.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Assessing the reliability of two toxicity scales: implications for interpreting toxicity data.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

A decision-analysis methodology for consideration of morbidity factors in clinical decision-making

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Patient participation in clinical decision-making for treatment of T3 laryngeal cancer: a comparison of state and process utilities

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Quality of life assessment and clinical decision-making*

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Trading treatment toxicity for survival in locally advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Accelerated fractionation radiotherapy for laryngeal cancer, acute, and late toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Mucosal regeneration during radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Twice-a-day radiotherapy for squamous cell carcinoma of the head and neck: the University of Florida experience

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Induction chemotherapy in advanced head and neck tumors: results of two randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Combined postoperative radiotherapy and Weekly Cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer: dose-limiting mucosal toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Toxicity of aggressive multimodality therapy including cisplatinum, bleomycin and methotrexate with radiation and/or surgery for advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Combined carboplatin plus bleomycin and conventional radiotherapy for advanced carcinomas of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Scoring oral mucositis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Late effects of hyperfractionated-radiotherapy for head and neck cancer--in response to Drs. Withers and Taylor, IJROBP 32:887-888; 1995

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment ... now!

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Late effects of radiation therapy in the head and neck region

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Analysis of late complications after rapid hyperfractionated radiotherapy in advanced head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Salvage surgery following radiation failure in squamous cell carcinoma of the supraglottic larynx

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Comparison of surgical complications after organ-preservation therapy in patients with stage III or IV squamous cell head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Surgery after organ preservation therapy. Analysis of wound complications

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Risk factors for complications in clean-contaminated head and neck surgical procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Complications following surgery for cancer of the larynx and pyriform fossa

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Surgical complications in patients with head and neck cancer receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

The recording of morbidity related to radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI)

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Assessment of quality of life in head and neck cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Longitudinal assessment of quality of life in laryngeal cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Head and neck cancer-specific quality of life: instrument validation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Opportunities and challenges: assessing quality of life in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Disease-specific quality of life: is it one construct?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Changes in quality-of-life scores in a population of patients treated for squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Quality of life outcomes after primary radiotherapy for squamous cell carcinoma of the base of tongue

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Quality of life of disease-free survivors of advanced (stage III or IV) oropharyngeal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Swallowing disorders in head and neck cancer patients treated with radiotherapy and adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

T stage and functional outcome in oral and oropharyngeal cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Super-supraglottic swallow in irradiated head and neck cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

Surgical variables affecting speech in treated patients with oral and oropharyngeal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900558-1

7 January 2021

10.1016/S0360-3016(99)00558-1

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10758302